What is Xentria?
Xentria operates as a specialized biotechnology firm dedicated to the end-to-end development of innovative drug candidates and intellectual property. By fostering authentic, collaborative partnerships, the company bridges the gap between initial conceptual research and commercial market entry. Its primary focus currently centers on the advancement of XTMAB-16, an investigational drug targeting pulmonary sarcoidosis. By providing a structured framework for drug development, Xentria assists developers in navigating the regulatory and clinical hurdles inherent in the pharmaceutical industry, ultimately aiming to improve patient outcomes through scientific rigor and strategic resource allocation.
How much funding has Xentria raised?
Xentria has raised a total of $25M across 1 funding round:
Private Equity
$25M
Private Equity (2022): $25M, investors not publicly disclosed
Key Investors in Xentria
Undisclosed Investors
What's next for Xentria?
With this major enterprise-level funding, Xentria is poised to scale its operational capabilities and deepen its research into rare disease treatments. The strategic deployment of this capital will likely focus on advancing XTMAB-16 through critical clinical trial phases, while simultaneously expanding the company's portfolio of life-sciences partnerships. As the firm matures, its ability to streamline the drug development lifecycle will be a key differentiator in a competitive biotech landscape. Investors and industry stakeholders will be monitoring the company's progress in clinical milestones and its capacity to translate complex intellectual property into viable, commercialized therapeutic solutions.
See full Xentria company page
